IMMUNOBIOLOGICAL ASPECTS OF THE APPLICATION OF THE NEW METABIOTICS
The paper presents the results of clinical and laboratory studies of a new metabiotic drug based on biologically active substances of the probiotic strain Bacillus subtilis B-3679. The assessment of the state and dynamics of changes in such integral immunological parameters characterizing the state of health of patients as the level of lysozyme activity and the concentration of s Ig A, and Ig A, M, G in salivary fluid of patients with chronic generalized periodontitis of moderate severity is given. It was found that the metabiotic was safe for use and had a pronounced positive clinical and therapeutic effect, normalizes the microbiocenosis of the oral cavity, which is accompanied by a decrease in the number of opportunistic microflora and an increase in the concentration of representatives of normal microflora. It was experimentally established that the studied metabiotic has a high antagonistic activity against various types of opportunistic microorganisms secreted in patients with periodontitis and promotes increased activity of salivary fluid lysozyme and immunoglobulins A and G.